The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase. (Q47674845)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23988379%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23988379%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

0 references

1 reference

based on heuristic

inferred from title

mucopolysaccharidosis II

1 reference

based on heuristic

inferred from title

Madhusudan Natarajan

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23988379%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

A J Barbier

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23988379%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

B Bielefeld

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23988379%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

D A H Whiteman

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23988379%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

A Pano

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23988379%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

D A Amato

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23988379%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

9 August 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23988379%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Molecular Genetics and Metabolism

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23988379%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

110

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23988379%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

303-310

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23988379%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23988379%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.08.002

7 January 2021

Initial report from the Hunter Outcome Survey

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.08.002

7 January 2021

Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.08.002

7 January 2021

Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.08.002

7 January 2021

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.08.002

7 January 2021

Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.08.002

7 January 2021

Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.08.002

7 January 2021

Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.08.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.08.002

7 January 2021

Analysis of survival by tumor response.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.08.002

7 January 2021

Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: A perspective from the Hunter Outcome Survey (HOS)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.08.002

7 January 2021

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47674845&oldid=1512406159"